Chylothorax due to thrombosis of the jugular and subclavian veins in a patient with gastric cancer: a case report

Autor: M. Ünal, E. Ünal, A. L. T. Imholz

Publikováno v: Journal of Medical Case Reports, Vol 17, Iss 1, Pp 1-5 (2023)

Abstract Background Chylothorax is a rare condition due to leakage of chyle in the thoracic cavity. When large amounts of chyle leak into the thoracic cavity, it can lead to severe respiratory, immune, and metabolic complications. Chylothorax has man

Externí odkaz: https://doaj.org/article/b74ed7002eb74a5785dcb55c4bc62eb3

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer

Autor: S. E. H. Detert Oude Weme, L. M. G. Hulskotte, W. L. Vervenne, A. L. T. Imholz, R. G. H. M. Cremers, K. Taxis, A. K. L. Reyners, I. R. F. van Berlo-van de Laar, F. G. A. Jansman, G. E. Benoist

Publikováno v: Clinical Pharmacokinetics.

BACKGROUND AND OBJECTIVE: Up to 90% of patients with castration-resistant prostate cancer (CRPC) will develop symptomatic bone metastases requiring pain medication, with opioids being the mainstay of therapy in treating moderate and severe pain. Enza

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5fb62a209f072608ec359bb7be8558
https://doi.org/10.1007/s40262-023-01255-1

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA)

Autor: G.A.P. Nieuwenhuijzen, R.A. Hellingman, Franchette W P J van den Berkmortel, S. Hovenga, H.M. Oosterkamp, T. van Dalen, Sabine C. Linn, E.J. van Dulken, Rudi M. H. Roumen, Maurice J.C. van der Sangen, R.C. van Doorn, M.O. den Boer, R. den Toom, Carolien H. Smorenburg, J.J.M. van der Hoeven, Aafke H. Honkoop, Irene E. G. van Hellemond, H. Potthoff, R. Koelemij, Frans L. G. Erdkamp, A. van Bochove, W.G. van Leeuwen-Breuk, R.J.B. Blaisse, A.M.T. van der Velden, Yvonne Kamm, E.J.C. Vriens, Judith R. Kroep, Erik W. Muller, W.J.B. Mastboom, R. van Hillegersberg, P.C. van der Velden, T. van Voorthuizen, Vivianne C. G. Tjan-Heijnen, J.M. Meerum Terwogt, M.M. Vleugel, A. Vos, J.J. Jansen, Jos J. E. M. Kitzen, G.S. Madretsma, R. Vree, J.K.S. Nuytinck, Luc J. A. Strobbe, J.H. van Dam, P.H.A. Nijhuis, Wilfred K. de Roos, P.P.J.B.M. Schiphorst, B. Jas, E.E.M. Schepers, Q. van Rossum-Schornagel, Petronella G. M. Peer, C.J. van Groeningen, J.G. Haasjes, M.J. Agterof, E.A. Kouwenhoven, Alexander L T Imholz, Caroline M. Seynaeve, M.A. Davidis-van Schoonhoven, M.A.J. de Roos, M.J.P.M. Govaert, J.M.A. Ketel, J.M.G.H. van Riel, M. Jagers, A.J. van Overbeeke, Aart Beeker, J.K. Maring, G.J. Veldhuis, J.W.S. Merkus, Maaike de Boer, Onno R. Guicherit, H.B.A.C. Stockmann, E. Janssens van Vliet, J. de Boer, D.F.S. Kehrer, I.E. Arntz, N.G.J. van Diemen, Koop Bosscha, Hiltje de Graaf, F.A.A. Valster, E.E.M. Weernink, C.T.A.M. van Rossum, M.A. van Dijk, B.C. Tanis, Astrid C P Swinkels, E.J.M. Siemerink, D.W. Sommeijer

Publikováno v: Tjan-Heijnen, V C G, van Hellemond, I E G, Peer, P G M, Swinkels, A C P, Smorenburg, C H, van der Sangen, M J C, Kroep, J R, De Graaf, H, Honkoop, A H, Erdkamp, F L G, van den Berkmortel, F W P J, de Boer, M, de Roos, W K, Linn, S C, Imholz, A L T, Seynaeve, C M & Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators 2017, ' Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA) : a randomised, phase 3 trial ', The Lancet Oncology, vol. 18, no. 11, pp. 1502-1511 . https://doi.org/10.1016/S1470-2045(17)30600-9
The Lancet Oncology, 18(11), 1502-1511
Lancet Oncology, 18, 11, pp. 1502-1511
LANCET ONCOLOGY, 18(11), 1502. Lancet Publishing Group
The Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet oncology, 18(11), 1502-1511. Elsevier Science
Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet Oncology, 18, 1502-1511

Item does not contain fulltext BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment perio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772ac93cab50bc31223c7dc7ba3cb291
https://doi.org/10.1016/s1470-2045(17)30600-9

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Autor: Alexander L T Imholz, Jesse J. Swen, Marlène H.W. van de Poel, Albert J. ten Tije, Paul Hamberg, Annemieke Cats, Femke M. de Man, Jos H. Beijnen, Miriam Koopman, Vincent O. Dezentjé, Emma Kienhuis, Caroline M.P.W. Mandigers, Peter Nieboer, Linda M. Henricks, Didier Meulendijks, André B.P. van Kuilenburg, Carin A.T.C. Lunenburg, Geert W.J. Frederix, Jan H.M. Schellens, Hilde Rosing, Henk-Jan Guchelaar, Helga J. Droogendijk, Rob L. H. Jansen, Frank J.F. Jeurissen, Ron H.J. Mathijssen, Hans Gelderblom, Arnold Baars, Geert Jan Creemers, Johanna E.A. Portielje, Erik van Werkhoven, Ron H.N. van Schaik

Publikováno v: European Journal of Cancer, 107, 60. Elsevier Ltd
European Journal of Cancer, 107, 60. Elsevier Limited
European journal of cancer (Oxford, England, 107, 60-67. Elsevier Limited
European Journal of Cancer, 107, 60-67
European Journal of Cancer
European Journal of Cancer, 107, 60-67. Elsevier Ltd.
European Journal of Cancer, 107, 60-67. ELSEVIER SCI LTD

Background: Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1847de5cbd772fe5bd914816205b488
https://dspace.library.uu.nl/handle/1874/389408

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Autor: Rob L. H. Jansen, Ron H.N. van Schaik, Henk-Jan Guchelaar, Johanna E.A. Portielje, Paul Hamberg, Didier Meulendijks, Jos H. Beijnen, Emma Kienhuis, Ron H.J. Mathijssen, Hans Gelderblom, Femke M. de Man, Frank J.F. Jeurissen, Geert W.J. Frederix, Arnold Baars, Jan H.M. Schellens, Helga J. Droogendijk, Marlène H.W. van de Poel, Hilde Rosing, Linda M. Henricks, Albert J. ten Tije, Annemieke Cats, Carin A.T.C. Lunenburg, Caroline M.P.W. Mandigers, Erik van Werkhoven, André B.P. van Kuilenburg, Peter Nieboer, Geert Jan Creemers, Miriam Koopman, Vincent O. Dezentjé, Alexander L T Imholz, Jesse J. Swen

Publikováno v: The Lancet Oncology, 19(11), 1459-1467
The Lancet Oncology, 19(11), 1459. Lancet Publishing Group
LANCET ONCOLOGY, 19(11), 1459. Lancet Publishing Group
The Lancet Oncology
Lancet oncology, 19(11), 1459-1467. Elsevier Science
lancet oncology, 19(11), 1459-1467. Lancet Publishing Group
Lancet Oncology, 19(11), 1459-1467. Lancet Publishing Group

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4283cc80c2ca08cc0f0a136e40a12b84
http://hdl.handle.net/1887/95617